Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-25-110824
Filing Date
2025-11-13
Accepted
2025-11-13 06:58:56
Documents
60
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q plx-20250930x10q.htm   iXBRL 10-Q 1152402
2 EX-10.1 plx-20250930xex10d1.htm EX-10.1 853206
3 EX-31.1 plx-20250930xex31d1.htm EX-31.1 12468
4 EX-31.2 plx-20250930xex31d2.htm EX-31.2 12642
5 EX-32.1 plx-20250930xex32d1.htm EX-32.1 6713
6 EX-32.2 plx-20250930xex32d2.htm EX-32.2 6741
7 GRAPHIC plx-20250930x10q005.jpg GRAPHIC 71042
8 GRAPHIC plx-20250930x10q006.jpg GRAPHIC 38391
9 GRAPHIC plx-20250930x10q007.jpg GRAPHIC 56626
10 GRAPHIC plx-20250930x10q008.jpg GRAPHIC 40218
  Complete submission text file 0001104659-25-110824.txt   6493059

Data Files

Seq Description Document Type Size
11 EX-101.SCH plx-20250930.xsd EX-101.SCH 35037
12 EX-101.CAL plx-20250930_cal.xml EX-101.CAL 51594
13 EX-101.DEF plx-20250930_def.xml EX-101.DEF 122019
14 EX-101.LAB plx-20250930_lab.xml EX-101.LAB 270017
15 EX-101.PRE plx-20250930_pre.xml EX-101.PRE 211859
63 EXTRACTED XBRL INSTANCE DOCUMENT plx-20250930x10q_htm.xml XML 759954
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33357 | Film No.: 251475310
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)